Norman J. Beauchamp Jr.
Executive Vice President for Health Sciences
Discovery to Impact
Breakthrough ideas change lives — but only when they move beyond the lab. Hear from national policy leaders, investors, and innovators as they discuss the critical role universities play in advancing research that serves the public good, fuels economic growth, and drives the future of American innovation.
Norman J. Beauchamp Jr.
Norman J. Beauchamp Jr., MD, MHS, serves as Executive Vice President for Health Sciences and Executive Dean of the School of Medicine at Georgetown University Medical Center. He is responsible for advancing the educational and research missions of Georgetown University Medical Center including the robust and full integration of a shared academic mission with its academic health system partner of MedStar Health. He is a tenured professor in the Department of Neurology, with a secondary appointment in the Department of Radiology at Georgetown University School of Medicine.
From 2019 to 2024, Beauchamp served as Executive Vice President for Health Sciences at Michigan State University. From 2016 to 2019, Beauchamp led the reorganization of the health colleges and the clinical practice at MSU into a unified health sciences structure to include the university’s clinical practice, osteopathic (DO) and allopathic (MD) medical colleges and the College of Nursing. He also led the creation of an anchor institution (large employers with significant infrastructure investment) in Grand Rapids and Detroit. In addition, Beauchamp also served as the co-architect, alongside leaders at Henry Ford Health, in establishing a 30-year partnership between MSU Health Sciences and Henry Ford Health. During MSU’s reorganization, Beauchamp held numerous roles including Dean, College of Human Medicine (2016-2019), Executive Dean of the Health Colleges (2018-2019), Assistant Vice President for Health Affairs (2018-2019) and Associate Provost for Health Affairs (2018-2024).
Beauchamp earned his medical degree at Michigan State University (MSU). He began his medical career at the School of Medicine at Johns Hopkins University, where he completed his radiology residency, neuroradiology fellowship, and neurointerventional training before joining their faculty in 1996. There, he served as vice chair for clinical operations and interim chair for radiology. He then moved to the University of Washington, where he spent 14 years as professor and chair of the Department of Radiology before joining MSU. While at University of Washington, he was also founding medical director of the Seattle King County Free Clinic.
Beauchamp is a leading physician/scientist in the diagnosis and treatment of stroke. As a neurointerventional radiologist, his research, published In more than 100 peer-reviewed papers, has focused on improving approaches to stroke prevention, diagnosis and treatment.
John F. Crowley
John F. Crowley
President and CEO, BIO
John F. Crowley, JD, MBA is the president and CEO of the Biotechnology Innovation Organization (BIO), the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. Crowley, a longtime BIO board member, was previously the founder and executive chairman of Amicus Therapeutics, a global biotechnology company focusing on developing treatments for rare genetic diseases. He served as CEO of Amicus from 2005 to 2022.
Crowley’s decades of biotech experience and deep passion for the field have made him a strong supporter of policies that empower innovation, enable entrepreneurship, and put people and patients first. His involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, Crowley left his position at Bristol Myers Squibb and became an entrepreneur as the co-founder, president and CEO of Novazyme Pharmaceuticals, a biotech startup conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children’s lives). In 2001, Novazyme was acquired by Genzyme Corporation, where Crowley continued to play a lead role in the development of a drug for Pompe disease as senior vice president, Genzyme Therapeutics.
Crowley and his family have been profiled numerous times on the front page of the Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children. The 2010 major motion picture, Extraordinary Measures, starring Brendan Fraser, Harrison Ford and Keri Russell, is inspired by the Crowley family journey. John is the author of a personal memoir, Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy.
John served as a commissioned officer in the U.S. Navy Reserve from 2005-2016. He is a veteran of the global war on terrorism, with service in Afghanistan. His assignments included service with the Joint Special Operations Command (JSOC), the Naval Special Warfare Development Group (NSWDG) and the Central Intelligence Agency (CIA). John attended the U.S. Naval Academy and went on to earn a B.S. in Foreign Service from Georgetown University, a JD from the University of Notre Dame Law School, and an MBA from the Harvard Business School.
The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame. He serves on the Board of Trustees at Notre Dame and on the Board of Directors of the United States Naval Academy Foundation. He is the former National Chairman of the Make-A-Wish Foundation of America and served on the board of BioNJ. John is a Henry Crown Fellow at the Aspen Institute. He was awarded a Doctor of Laws Degree (Honoris Causa) from the University of Notre Dame, where he delivered the commencement address to the Class of 2020. In 2023, he was inducted as a member of the Horatio Alger Association.
Kiran Reddy
Kiran Reddy
Sr. Managing Director, Blackstone Life Sciences- Cambridge
Kiran Reddy, MD, MBA is a senior managing director in the Blackstone Life Sciences group having joined in May 2020. Reddy was previously the president and CEO of Praxis Precision Medicines, which he co-founded in November 2016.
Previously, Reddy was at Biogen where he was part of the corporate develop and strategy leadership team. Reddy was also an associate partner at Third Rock Ventures. He supported and managed various portfolio companies in addition to focusing on new company formation and new investments. He was part of the founding team and interim chief business officer for SAGE Therapeutics through its IPO. Reddy was part of the team that launched Foundation Medicine, and he has served as a Board Observer for Alnara pharmaceuticals, Rhythm pharmaceuticals and PanOptica pharmaceuticals.
Reddy holds MD and MBA degrees from Georgetown University. He completed his internship in medicine and his neurology residency at Harvard/Massachusetts General Hospital. Reddy was previously a Howard Hughes science fellow and has authored several peer-reviewed scientific papers in the field of epilepsy, neuroimmunology and neurodegenerative diseases.
Tatiana Litvin-Vechnyak
Tatiana Litvin-Vechnyak
Vice President, Technology Commercialization, Georgetown University
In February 2023, Tatiana Litvin-Vechnyak, PhD, assumed the role of Vice President for Technology Commercialization at Georgetown University, where she spearheads technology transfer initiatives to foster innovation and faculty entrepreneurship. Under her leadership, the Office of Technology Commercialization has seen significant growth and evolution across its core programs.
Litvin-Vechnyak secured a Build to Scale grant from the US Economic Development Administration (EDA) that launched Georgetown Tech Ventures — a program that has more than doubled the number of technology startups emerging from the university. The university’s gap funding program evolved into the Evergreen Gap Fund, a reimagined model that ensures a sustained university contribution to the funding mechanism itself, creating a self-renewing source of early-stage capital to bridge the path from academic research to commercialization. The patent awards program was similarly strengthened to better recognize and incentivize faculty innovation. And under her leadership, Georgetown launched its inaugural Research & Innovation Showcase — an annual event that has quickly become a flagship convening for the university’s innovation community, bringing together researchers, industry leaders, investors, and entrepreneurs to accelerate the translation of Georgetown discoveries into real-world impact.
With more than 20 years of expertise in intellectual property protection, business development, and licensing, Litvin-Vechnyak previously held the position of Associate Vice President of Innovation Ventures at Rutgers University. During her tenure at Rutgers, she achieved meaningful milestones, including overhauling patent policies, establishing a highly successful fellowship program, and making pivotal contributions to the launch of the TechAdvance funding initiative.
Litvin-Vechnyak holds a PhD in pharmacology and is a duly registered patent agent. She actively engages in professional organizations, frequently delivering intellectual property and technology licensing talks. Beyond her professional career, Litvin-Vechnyak is an avid sailor who, together with her husband, supports sailing endeavors within her family at their local club community.
Stephen J. Susalka
Stephen J. Susalka
Chief Executive Officer, AUTM
Stephen J. Susalka, PhD, works to ensure that AUTM serves the needs and interests of its members through strategic planning, outreach and advocacy, while empowering association members and promoting the profession.
A regular speaker on technology transfer issues, Susalka has presented on Capitol Hill and internationally on topics ranging from the evolution of the technology transfer profession to start-up formation.
Before joining AUTM, Susalka served as associate director for commercialization at Wake Forest Innovations, where he was responsible for commercializing high-impact inventions, and drafting, negotiating and executing a wide variety of licensing and start-up transactions.
Susalka is a registered US patent agent and a past board member of multiple Wake Forest-affiliated start-ups. Steve has also led the Winston-Salem Technology Council to retain and grow local technology businesses to strengthen the economy.